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Schizophrenia is characterized by positive and negative symptoms and cognitive dys-
function. The glutamate hypothesis of schizophrenia has been hypothesized to explain 
the negative symptoms and cognitive deficits better than the dopamine hypothesis alone. 
Therefore, we aimed to evaluate whether glutamatergic variants such as d-amino acid 
oxidase (DAO), DAO activator (DAOA)/G72, and neuregulin 1 (NRG1) single-nucleotide 
polymorphisms (SNPs) and their mRNA levels predicted (i) transition to schizophrenia 
spectrum disorders and (ii) research domain criteria (RDoC) domains, mainly negative 
valence and cognitive systems. In a 3-year prospective study cohort of 185 individuals 
(age: 13–35 years) at high risk and ultra-high risk (UHR) for psychosis, we assessed 
DAO (rs3918347, rs4623951), DAOA (rs778293, rs3916971, rs746187), and NRG1 
(rs10503929) SNPs and their mRNA expression. Furthermore, we investigated their 
association with RDoC domains, mainly negative valence (e.g., anxiety, hopelessness) 
and cognitive (e.g., perception disturbances, disorganized symptoms) systems. NRG1 
rs10503929 CC + CT versus TT genotype carriers experienced significantly more disor-
ganized symptoms. DAOA rs746187 CC versus CT + TT genotype, DAOA rs3916971 
TT versus TC +  CC genotype, and DAO rs3918347 GA +  AA versus GG genotype 
carriers experienced nominally more hopelessness, visual perception disturbances, and 
auditory perception disturbances, respectively. The schizophrenia risk G-allele of DAO 
rs3918347 nominally increased risk for those UHR individuals with attenuated positive 
symptoms syndrome. No association between DAO, DAOA, NRG1 SNPs, and conver-
sion to schizophrenia spectrum disorders was observed. Our findings suggest that DAO, 
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DAOA, and NRG1 polymorphisms might influence both RDoC negative valence and 
cognitive systems, but not transition to schizophrenia spectrum disorders.
Keywords: d-amino acid oxidase/dAO/dAAO, d-amino acid oxidase activator/g72/DaOa, neuregulin 1/nrg1, 
attenuated positive symptoms syndrome/aPss, single-nucleotide polymorphism/snP, research domain criteria/
rDoc
glutamatergic system is an attractive therapeutic target (18). Meta-
analyses have reported that addition of NMDA receptor agonist 
d-serine and glycine transporter type 1 inhibitor sarcosine as an 
adjunct to antipsychotics reduce total and negative symptoms 
(19, 20). Based on these observations, the glutamate hypothesis 
is thought to describe the pathophysiology underlying nega-
tive symptoms and cognitive deficits better than the dopamine 
hypothesis (21–23). NMDA receptor hypofunction might lead to 
decreased dopamine activity in the mesocortical pathway, which 
may manifest as negative symptoms and cognitive dysfunction 
in schizophrenia (24). The NMDA receptor hypofunction theory 
proposed in schizophrenia might be partly explained by increased 
DAO activity modulated by DAOA leading to decreased d-serine, 
a co-agonist of NMDA receptors (25). The function of NRG1 is 
mediated by binding to receptor tyrosine kinases called ErbB 
(ErbB3 and ErbB4), and an altered NRG1/ErbB4 signaling is 
thought to result in NMDA receptor hypofunction (26, 27). These 
studies highlight the potential pathogenic link between NMDA 
receptor hypofunction and dysregulation of DAO, DAOA, and 
NRG1 genes.
The National Institute of Mental Health started the research 
domain criteria (RDoC) initiative to guide and organize research 
in psychiatric disorders beyond the typical diagnostic classifica-
tion approach (28). This initiative provides a non-disease-based 
structured conceptual framework to understand the dimensional 
range of human behavior from normal to abnormal by integrating 
multiple levels of information (from genomics to self-reports). 
The RDoC represents a paradigm shift from Diagnostic and 
Statistical Manual of Mental Disorders (DSM)/International 
Classification of Diseases (ICD) to dimensional approaches with 
an aim to integrate basic research and psychopathology (29).
In this study, we aimed (1) to identify predictive glutamatergic 
genetic polymorphisms in at-risk individuals for transition to 
schizophrenia spectrum disorders, (2) to identify endopheno-
types potentially linked to the glutamatergic system in at-risk 
individuals using RDoC constructs, and (3) to evaluate differ-
ences in DAO, DAOA, and NRG1 mRNA levels across clinical 
and RDoC domains.
MaTerials anD MeThODs
study Population
Participants were recruited by the “Early Recognition and 
Intervention Program for Psychosis and Bipolar Disorder” pro-
ject as part of the Zurich Program for Sustainable Development 
of Mental Health Services (ZInEP)1 in the Canton of Zurich, 
1 http://www.zinep.ch.
inTrODUcTiOn
Schizophrenia is a chronic and debilitating disorder, preceded by 
a broad range of symptoms. The emergence of psychotic features 
in schizophrenia is typically between the late teens and mid-30s 
(1). Early recognition of individuals at-risk for psychosis and 
the provision of early intervention is likely to be associated with 
improved outcomes (2). Individuals at clinical risk for psychosis 
are identified by two complementary approaches: the high risk 
(HR) and the ultra-high risk (UHR) criteria. The HR concept is 
based on basic symptoms and comprises two partially overlap-
ping risk constellations, the cognitive-perceptive (COPER) basic 
symptoms and the cognitive disturbances (COGDIS) (3, 4). The 
UHR criteria comprise attenuated positive symptoms syndrome 
(APSS), brief limited intermittent psychotic symptoms (BLIPS), 
and a combination of a risk factor for psychosis and a recent func-
tional decline (5). A meta-analysis of 27 studies showed that 18, 
21, 27, and 32% of individuals at-risk for psychosis (HR + UHR) 
transitioned to psychotic disorders at 6, 12, 24, and 36 months 
of follow-up, respectively (6). This meta-analysis also showed 
that the mean transition risk was 49, 28, and 22% using the HR 
approach, UHR approach, and when combining both HR and 
UHR approaches, respectively (6). One study reported that about 
one-third of individuals at UHR for psychosis transitioned to 
psychosis (7). Our recent study, using a multivariable prediction 
model, demonstrated that as expected, UHR criteria predicted 
conversion to psychosis but combining HR and UHR criteria 
in this help-seeking at-risk population did not improve the 
predictive accuracy of UHR alone (8). Therefore, it is important 
to optimize the identification of individuals at HR/UHR for 
psychosis by minimizing the false positive rate and improving 
the true positive prediction rate of conversion to psychosis.
The estimated heritability in schizophrenia is around 
60–80% (9). Studies have demonstrated an association between 
schizophrenia and d-amino acid oxidase (DAO), DAO activa-
tor (DAOA)/G72, and neuregulin 1 (NRG1) single-nucleotide 
polymorphisms (SNPs) (10, 11). DAOA and NRG1 polymor-
phisms were shown to predict the transition to schizophrenia in 
individuals at HR/UHR for psychosis (12–14). Genetic studies 
in schizophrenia have shown the association of neurocognitive 
endophenotypes with several glutamatergic gene polymorphisms 
including NRG1 (15–17). These studies suggest that genetic vari-
ations and neurocognitive endophenotypes may help to improve 
the prediction accuracy of clinical symptoms and HR/UHR 
criteria for transition in an at-risk population.
The glutamate hypothesis of schizophrenia originated from 
the observation that N-methyl-d-aspartate (NMDA) receptor 
blockers like ketamine induced schizophrenia-like symptoms. 
As antipsychotics (dopamine D2 receptor antagonists) have 
little effect on negative symptoms and cognitive deficits, the 
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Switzerland. The detailed design, inclusion, and exclusion crite-
ria of the study were described in our previous studies (30, 31). 
A total of 185 individuals aged 13–35 years at HR/UHR for psy-
chosis were assessed at baseline and were subsequently followed-
up at 6, 12, 24, and 36 months for the transition to schizophrenia. 
At 36  months follow-up, 50% of individuals (n =  93) dropped 
out of the study. The dropouts were due to refusal to participate 
in the study in most of the cases and due to non-response after 
contacting in few cases. However, we are unable to give exact 
numbers of individuals who refused to participate or who did 
not respond due to missing information in several study par-
ticipants. Individuals at HR for psychosis were assessed using the 
Schizophrenia Proneness Instrument-Child and Youth version 
(SPI-CY) (age < 18 years) (32, 33) or Schizophrenia Proneness 
Instrument-Adult version (SPI-A) (age ≥ 18 years) (34) and were 
included when they had one COPER basic symptom or at least 
two COGDIS. Individuals at UHR for psychosis were assessed 
using the Structured Interview for Prodromal Syndromes (SIPS) 
(35, 36) and were included when they met criteria for the APSS 
or the BLIPS or the state-trait criteria (>30% reduction in global 
assessment of functioning in the past year plus either schizotypal 
personality disorder or a first-degree relative with psychosis). 
The transition to schizophrenia was defined according to ICD-
10 criteria (37). The severity of positive and negative symptoms 
was assessed using the Positive and Negative Syndrome Scale 
(PANSS) (38), severity of depressive symptoms with the Calgary 
Depression Rating scale for Schizophrenia (CDSS) (39), and anxi-
ety symptoms with the Beck Anxiety Inventory (BAI) (40). The 
demographic and diagnostic characteristics of the study popula-
tion are shown in Table S1 in Supplementary Material. This study 
was approved by the Cantonal Ethics Commission of Zurich (Ref. 
Nr. EK: E-63/2009) and complies with the Declaration of Helsinki. 
Informed written consent was obtained from adult participants 
and legal guardians of minors, and written assent was obtained 
from minors.
Phenotypic Domains
The participants were grouped into clinical phenotypes (cases 
versus controls) namely, converters to schizophrenia spectrum 
disorders (n = 27), i.e., schizophrenia, schizophreniform disor-
der, and acute psychotic disorder, versus non-converters (n = 65) 
at 36 months follow-up [dropouts (n = 93)], and APSS (n = 98) 
group versus all other help-seeking individuals (BLIPS, state-trait 
criteria, COGDIS, COPER; n =  87) at baseline. The transition 
to schizophrenia was defined according to ICD-10 criteria (37).
First, we grouped our cohort as per the factor structure of the 
PANSS, concentrating on negative symptoms and general psy-
chopathology (38). As we did not find any significant differences 
in negative symptoms (sum score of negative (N1–N7) PANSS 
subscale) and general psychopathology (sum score of general psy-
chopathology (G1–G16) PANSS subscale) across DAO, DAOA, 
and NRG1 SNPs, we then decided to use an exploratory approach 
by focusing on subgroups of psychopathology constructs defined 
according to the RDoC domains. The RDoC framework consists 
of five domains namely, negative valence systems, positive 
valence systems, cognitive systems, systems for social process, 
and arousal/regulatory systems (41). In this study, we decided to 
concentrate on two RDoC domains: negative valence systems and 
cognitive systems, due to the potential role of DAO, DAOA, and 
NRG1 polymorphisms in the glutamate hypothesis of schizophre-
nia, as it appears to explain the pathogenesis of negative symp-
toms and cognitive deficits better than the dopamine hypothesis 
(22, 23, 42) and unavailability of relevant neuropsychological 
scales in our study to create the positive valence domain. Negative 
valence systems focus on responses to aversive situations, such as 
fear, anxiety, and loss. Cognitive systems concentrate on various 
cognitive processes, such as perception, language, memory, and 
cognitive control. Within negative valence systems, we focused 
on the constructs of threat (acute and sustained) and loss. The 
negative valence system construct of threat was assessed by the 
total score of BAI with higher BAI scores pointing to increased 
severity of anxiety (40). The negative valence system construct 
loss was assessed by the response to the CDSS item 2 “hopeless-
ness,” which can be scored as 0 (absent), 1 (mild), 2 (moderate), or 
3 (severe) (39). Within cognitive systems, we chose the constructs 
of perception (visual and auditory) and cognitive control. The 
cognitive system construct visual perception was assessed by 
summing the following four SPI-A (and equivalent SPI-CY) items 
O4 (other visual perception disturbances), F1 (hypersensitivity to 
light), F2 (photopsia), and F3 (micropsia/macropsia), with higher 
scores pointing to more frequent disturbances in visual percep-
tion. The cognitive system construct of auditory perception was 
assessed by summing the following three SPI-A (and equivalent 
SPI-CY) items O5 (other acoustic perception disturbances), F4 
(hypersensitivity to sounds/noise), and F5 (changed intensity/
quality of acoustic stimuli), with higher scores pointing to more 
frequent disturbances in auditory perception. The cognitive 
system construct of cognitive control was obtained by summing 
the following four SIPS disorganization items D1, D2, D3, and D4 
(35, 36), with higher scores indicating more severe disturbance in 
disorganized symptoms.
The above-mentioned scales used to tap into RDoC domains 
were assessed at baseline and last-available follow-up until 
36  months. As there was a dropout rate of 50% at 36  months, 
if there were no data available at 36 months, we took the scores 
from the last follow-up that the individual attended (i.e., 6 or 12 
or 24 months).
TaqMan snP genotyping
The study population was genotyped for DAO (rs3918347, 
rs4623951), DAOA (rs778293, rs3916971, rs746187), and NRG1 
(rs10503929) SNPs. These SNPs were selected based on previ-
ously reported significant association with schizophrenia (10, 
43). In our recent meta-analysis, we found a significant associa-
tion of DAO rs4623951 [odds ratio (OR) = 0.88; minor allele: C], 
DAOA rs778293 (OR = 1.17; minor allele: G), DAOA rs3916971 
(OR = 0.84; minor allele: T), and NRG1 rs10503929 (OR = 0.89; 
minor allele: C) with schizophrenia (11). In this study, the carriers 
of the risk allele of DAO, DAOA, and NRG1 SNPs were anticipated 
to have worse psychopathology scores in RDoC-negative valence 
and cognitive system constructs. DNA was isolated from whole 
blood ethylenediaminetetraacetic acid tubes collected from the 
study population using QIAamp DNA Blood Maxi Kit (Qiagen) 
as per manufacturer’s protocol. A spectrophotometer (NanoVue 
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Plus, GE) was used to measure DNA concentrations, A260/A280, 
and A260/A230 ratios. The study population was genotyped for 
DAO (rs3918347 assay number: C_27937201_10, rs4623951 assay 
number: C_32177440_10, both from Applied Biosystems, USA), 
DAOA (rs778293 assay number: C_8704507_10, rs3916971 
assay number: C_27495752_10, rs746187 assay number: 
C_1925241_10, all from Applied Biosystems, USA), and NRG1 
(rs10503929, assay number: C_2870393_10, Applied Biosystems, 
USA) SNPs (44). DNA (10 ng/µl); TaqMan® Genotyping Master 
Mix (Applied Biosystems, USA); and above-mentioned DAO, 
DAOA, and NRG1 SNP Genotyping Assays (Applied Biosystems, 
USA) were combined in a 384-well plate. Real-time polymerase 
chain reaction (PCR) was performed in a C1000™CFX384TM 
Thermal cycler (Bio-Rad) using TaqMan® SNP Genotyping Assay 
PCR standard protocol. The allelic discrimination program of 
Bio-Rad CFX Manager™ Software version 2.1 was used to deter-
mine genotypes (44). Samples were run in duplicates to ensure 
correct results. In case of ambiguity in duplicates, genotyping was 
repeated in a separate run to ensure correct results. No-template 
controls were included in every run to exclude impurities.
Quantification of NRG1, DAO, and DAOA 
mrna levels Using Quantitative real-
time reverse Transcription-Polymerase 
chain reaction (qrT-Pcr)
RNA was isolated from whole blood collected from the study 
population using PAXgene Blood RNA Kit (Qiagen) according 
to manufacturer’s protocol. A spectrophotometer (NanoVue Plus, 
GE) was used to measure RNA concentrations, A260/A280, and 
A260/A230 ratios. RNA integrity was analyzed using Experion 
automated electrophoresis system (Bio-Rad) in a subset of 
samples to ensure RNA integrity number/RNA quality indica-
tor >7. RNA (500  ng) was reverse transcribed using iScript™ 
cDNA Synthesis Kit (Bio-Rad) as per manufacturer’s protocol. 
In a subset of samples, negative controls were prepared with 
RNA using iScript™ cDNA Synthesis Kit (Bio-Rad) without 
reverse transcriptase enzyme as per manufacturer’s protocol. 
qRT-PCR was performed using cDNA, QuantiFast SYBR Green 
PCR kit (Qiagen), 1 µM NRG1 primer (QT00061964, Qiagen), 
and reference genes [β-actin (ACTB) (QT01680476), aminole-
vulinate synthetase (ALAS1) (QT00073122), ribosomal protein 
L13a (RPL13A) (QT00089915), alanyl-tRNA synthetase (AARS) 
(QT00054747), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (QT01192646), peptidyl prolyl isomerase A (PPIA) 
(QT00866137), and X-prolyl aminopeptidase1 (XPNPEP1) 
(QT00051471); all from Qiagen]. NRG1 mRNA levels were 
normalized to the references genes (44). PCR efficiencies were 
calculated using LinReg PCR program (45), and mean PCR effi-
ciencies for all studied amplicons were found to be between 91 
and 93%. Normalized NRG1 mRNA levels were quantified using 
qBASE plus software (Biogazelle), which utilizes gene-specific 
amplification efficiencies and allows normalization with multiple 
reference genes (46).
We performed qRT-PCR to detect DAO mRNA using 
DAO primers described by Verrall et  al. (47) and predesigned 
primers [qHsaCID0011122 and qHsaCEP0058247 (Bio-Rad), 
Hs.PT.58.3248433 and Hs.PT.58.45768871 (IDT)]. We per-
formed qRT-PCR to detect DAOA mRNA using primers for 
DAOA gene described by Benzel et al. (48), Cheng et al. (49), and 
pre-designed primers [QT00058863 (Qiagen), Hs.PT.58.555086 
(IDT), 4331182 (ThermoFisher scientific), qHsaCEP0024792 
(Bio-Rad)]. QuantiTect Whole Transcriptome Kit (207043, 
Qiagen) followed by qRT-PCR was also used to detect DAO and 
DAOA mRNA levels (44). However, we were unable to quantify 
DAO and DAOA mRNA with the aforementioned methods in the 
whole blood as either no signal was observed or genomic DNA 
was amplified concomitantly.
statistical analysis
The results from SNP genotyping was analyzed using PLINK 
software (50). The minor allele frequency (MAF) and deviation 
from Hardy-Weinberg Equilibrium (HWE) was computed using 
PLINK software, and p <  0.05 was considered as statistically 
significant. The DAO (rs3918347), DAOA (rs3916971, rs778293, 
rs746187), and NRG1 (rs10503929) SNPs were in HWE (p > 0.05), 
and the MAF of DAO, DAOA, and NRG1 SNPs were similar to 
HapMap CEU MAF (Table S5 in Supplementary Material). The 
DAO rs4623951 SNP deviated from the HWE (p < 0.05; Table 
S4 in Supplementary Material). The differences in allele and 
genotype frequencies across clinical phenotypes (cases versus 
controls) were assessed using Chi-square test, and p < 0.05 was 
considered as statistically significant. The OR, 95% CI, and p value 
for SNP models (allelic, dominant, and recessive) across clinical 
phenotypes were calculated from allele/genotype frequencies 
using an online OR calculator,2 and p value was adjusted based on 
the number of analyzed SNPs (Bonferroni correction, p < 0.008). 
The post hoc power analyses for association of DAO, DAOA, and 
NRG1 SNPs with converters to schizophrenia spectrum disorders 
versus non-converters (Table S5 in Supplementary Material) and 
APSS versus all other help-seeking group were conducted using 
Fisher’s exact test of independence in G*Power software (51), the 
calculated OR was used, and the alpha level was set at 0.05.
IBM® SPSS® Statistics (version 21) software was used for 
statistical analysis. Shapiro–Wilk test with Lilliefors significance 
correction was used to assess the normality of the distribution 
of NRG1 gene expression and clinical scales (BAI, CDSS, SPI-A/
SPI-CY, SIPS, and PANSS). NRG1 gene expression and clinical 
scales showed both normal and non-normal distribution. We 
used non-parametric tests even for normally distributed data to 
maintain consistency between statistical evaluations. The differ-
ences in RDoC domains (negative valence and cognitive systems) 
across models (genotypic, dominant, recessive) were assessed 
using Mann–Whitney test (for two groups) or Kruskal–Wallis test 
(for >2 groups), and p values were adjusted based on the number 
of constructs analyzed (Bonferroni correction, p <  0.008). The 
differences in NRG1 mRNA levels across clinical phenotypes 
were assessed using Mann–Whitney test, and p < 0.05 was set as 
statistically significant. The post hoc power analyses for RDoC-
negative valence and cognitive systems across DAO, DAOA, and 
2 https://www.medcalc.org/calc/odds_ratio.php.
FigUre 1 | Differences in research domain criteria (RDoC) negative valence system loss across d-amino acid oxidase activator (DAOA) rs746187 genotypes. 
Differences in Calgary Depression Scale for Schizophrenia (CDSS) item 2: hopelessness scale across DAOA rs746187 genotypes in genotype (a), dominant  
(B), and recessive (c) model at baseline and last-available follow-up time point until 36 months. Data are presented as mean ± SEM; #0.008 < p < 0.05 (significant 
without Bonferroni correction).
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NRG1 SNPs were conducted using analysis of variance test for 
three groups or t-test for two groups in G*Power software (51), 
the effect sizes were determined from means of neuropsychologi-
cal scales used in RDoC-negative valence and cognitive systems, 
and the alpha level was set at 0.05 (Table S7 in Supplementary 
Material). The differences in NRG1 mRNA levels across NRG1 
rs10503929 SNP genotypes was assessed using Kruskal–Wallis 
test, and across dominant (CC + CT, TT) and recessive models 
(CC, CT + TT) were assessed using Mann–Whitney test, with 
p  <  0.05 being set as statistically significant. The correlation 
between NRG1 gene expression and RDoC domains (negative 
valence and cognitive systems) was assessed using Spearman’s 
rank correlation test, and p <  0.05 was considered statistically 
significant.
resUlTs
The DAO (rs3918347), DAOA (rs3916971, rs778293, rs746187), 
and NRG1 (rs10503929) SNPs were in HWE (p > 0.05), and the 
MAF of DAO, DAOA, and NRG1 SNPs were similar to HapMap 
CEU MAF (Table S2 in Supplementary Material).
DAO, DAOA, and NRG1 Polymorphisms 
across clinical Phenotypes
There were no significant associations between DAO, DAOA, and 
NRG1 SNPs with converters to schizophrenia spectrum disorders 
compared to non-converters at 36  months follow-up (power 
range: 0.05–0.31; Table S3 in Supplementary Material). However, 
there was a nominal association (p > 0.008) of DAO rs3918347 
with APSS compared to all other help-seeking group at baseline, 
and the G-allele had a tendency to be a risk allele for APSS 
(OR = 1.84, 95% CI = 1.13–3.01, p = 0.01), with a power of 0.76 
(Table S4 in Supplementary Material). There were no significant 
associations between the rest of the DAO, DAOA, NRG1 SNPs 
and APSS (power range: 0.05–0.89; Table S4 in Supplementary 
Material).
DAO, DAOA, and NRG1 Polymorphisms 
across rDoc Domains
d-amino acid oxidase activator rs746187 recessive (CC) geno-
type carriers experienced nominally more hopelessness (higher 
item 2 score, CDSS) than CT + TT genotype carriers at the last-
available follow-up time point (LA) until 36 months (p = 0.04) 
analyzed by Mann–Whitney test (RDoC-negative valence sys-
tem: loss; Figures 1A–C; power = 0.62; effect size = 0.55; Table 
S8 in Supplementary Material). DAOA rs3916971 recessive (TT) 
genotype carriers experienced nominally more disturbances in 
visual perception (higher sum of O4 + F1 + F2 + F3, SPI-A) than 
TC + CC genotype carriers at LA until 36 months (p = 0.009) 
analyzed by Mann–Whitney test (RDoC cognitive system: visual 
perception; Figures  2A–C; power =  0.28; effect size =  0.34; 
Table S8 in Supplementary Material). Individuals with DAOA 
rs3916971 TC +  CC versus TT genotype improved and had 
fewer visual perceptual disturbances at LA until 36  months 
compared to baseline, but at LA until 36 months versus base-
line, they continued to have less visual perceptual disturbances 
than individuals with TT genotype (Figure  2C). There were 
no significant differences in negative valence (threat; Table S5 
in Supplementary Material; power range: 0.05–0.72, Table S8 
in Supplementary Material), auditory perception disturbances 
(Table S6 in Supplementary Material; power range: 0.05– 
0.56, Table S8 in Supplementary Material), and cognitive control 
(Table S7 in Supplementary Material; power range: 0.05–0.31, 
Table S8 in Supplementary Material) in individuals with DAOA 
SNP genotypes (rs3916971, rs778293, rs746187).
d-amino acid oxidase rs3918347 GA +  AA genotype carriers 
experienced nominally (p =  0.04) more disturbances in audi-
tory perception (higher sum of O5 + F4 + F5, SPI-A) than GG 
FigUre 3 | Differences in research domain criteria (RDoC) cognitive system auditory perception across d-amino acid oxidase activator (DAO) rs3918347 genotypes. 
Differences in Schizophrenia Proneness Instrument-Adult version (SPI-A) O5 + F4 + F5 sum score across DAO rs3918347 genotypes in genotype (a), dominant  
(B), and recessive (c) model at baseline and last-available follow-up time point until 36 months. Data are presented as mean ± SEM; #0.008 < p < 0.05 (significant 
without Bonferroni correction).
FigUre 2 | Differences in research domain criteria (RDoC) cognitive system visual perception across d-amino acid oxidase activator (DAOA) rs3916971  
genotypes. Differences in Schizophrenia Proneness Instrument-Adult version (SPI-A) O4 + F1 + F2 + F3 sum score across DAOA rs3916971 genotypes in  
genotype (a), dominant (B), and recessive (c) model at baseline and last-available follow-up time point until 36 months. Data are presented as mean ± SEM; 
#0.008 < p < 0.05 (significant without Bonferroni correction).
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genotype carriers at baseline analyzed by Mann–Whitney test 
(RDoC cognitive system: auditory perception; Figures  3A–C; 
power  =  0.41; effect size  =  0.44; Table S8 in Supplementary 
Material). Individuals with DAO rs3918347 GA + AA versus GG 
genotype improved and had lesser auditory perceptual distur-
bances at LA until 36 months compared to baseline, but at LA 
until 36  months versus baseline, they continued to experience 
more auditory perceptual disturbances than individuals with CC 
genotype (Figure 3C). We did not find significant differences in 
negative valence systems (anxiousness and hopelessness; Table S5 
in Supplementary Material; power range: 0.05–0.92, Table S8 in 
Supplementary Material), visual perception disturbances (Table 
S6 in Supplementary Material; power range: 0.05–0.57, Table 
S8 in Supplementary Material), and cognitive control (Table S7 
in Supplementary Material; power range: 0.05–0.22, Table S8 in 
Supplementary Material) in individuals with DAO (rs3918347, 
rs4623951) SNP genotypes.
Neuregulin 1 rs10503929 CC + CT genotype carriers had sig-
nificantly (p = 0.001) more disorganized symptoms (higher sum 
of the D1–D4 score, SIPS) than TT genotype carriers at baseline 
analyzed by Mann–Whitney test (RDoC cognitive system: cogni-
tive control; Figures 4A–C; power = 0.99; effect size = 0.59; Table 
S8 in Supplementary Material). There were no significant differ-
ences in negative valence systems (anxiousness and hopelessness; 
Table S5 in Supplementary Material; power range: 0.07–0.51, 
Table S8 in Supplementary Material) and visual and auditory 
FigUre 4 | Differences in research domain criteria (RDoC) cognitive system cognitive control across neuregulin 1 (NRG1) rs10503929 genotypes. Differences in 
Structured Interview for Prodromal Syndromes (SIPS) sum score of D1-D4 across NRG1 rs10503929 genotypes in genotype (a), dominant (B), and recessive  
(c) model at baseline and last-available follow-up time point until 36 months. Data are presented as mean ± SEM; *p < 0.008 (significant with Bonferroni correction).
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perception disturbances (Table S6 in Supplementary Material; 
power range: 0.05–0.36, Table S8 in Supplementary Material) in 
individuals with NRG1 (rs10503929) SNP genotypes.
To analyze the effect of age on RDoC domains across DAO, 
DAOA, and NRG1 SNPs, we performed an analysis of covariance 
with age as a covariate after transformation of not normally dis-
tributed BAI, SPI-A, and SIPS data, as described previously (52). 
We did not find a significant effect of age on differences in RDoC 
domains across DAO, DAOA, and NRG1 SNPs (data not shown).
NRG1, DAO, and DAOA mrna expression 
across rDoc and clinical Domains
There was a significant positive correlation between increased 
NRG1 mRNA levels and higher scores on the RDoC-negative 
valence system loss at LA until 36 months (Table S9 in Supple-
mentary Material). Apart from this, there were no significant 
correlations between NRG1 mRNA levels and RDoC domains at 
baseline and at LA until 36 months (Table S9 in Supplementary 
Material). There were no statistically significant differences in 
NRG1 mRNA levels across clinical phenotypes (Table S10 in 
Supplementary Material). We did not find significant differences 
in NRG1 mRNA levels across NRG1 rs10503929 SNP genotypes, 
dominant, and recessive models analyzed by Mann–Whitney and 
Kruskal–Wallis tests (Table S11 in Supplementary Material). We 
were unable to quantify DAO and DAOA mRNA levels in the 
whole blood of at-risk population.
DiscUssiOn
In this 3-year follow-up study of 185 at-risk individuals, NRG1 
rs10503929 CC + CT versus TT genotype carriers experienced 
significantly more disorganized symptoms, DAOA rs746187 CC 
versus CT + TT genotype, DAOA rs3916971 TT versus TC + CC 
genotype, and DAO rs3918347 GA +  AA versus GG genotype 
carriers experienced nominally more hopelessness, visual percep-
tion disturbances, and auditory perception disturbances, respec-
tively. Moreover, we found no significant association between 
DAO, DAOA, NRG1 SNPs, and conversion to schizophrenia 
spectrum disorders; however, we did find a nominally increased 
risk for APSS with the G-allele of DAO rs3918347 carriers.
The DAO, DAOA, and NRG1 SNPs did not predict conversion 
to schizophrenia spectrum disorders at 36  months follow-up. 
This lack of association may be due to a low conversion rate of 
14.6%, a high dropout rate of 50% at 36 months follow-up, and 
that the comparison group of non-converters was not a healthy 
control group but rather a heterogeneous group of HR and UHR 
individuals. In this heterogeneous at-risk population, individuals 
are likely to be on different developmental trajectories of/toward 
various neuropsychiatric disorders, which might have further 
complicated the genetic prediction of transition to schizophre-
nia in our study. Furthermore, our conversion group not only 
contained patients with schizophrenia but also patients with 
other schizophrenia spectrum disorders. Thus, recruiting a more 
homogeneous at-risk population has been more appropriate 
(53, 54). In contrast to previous meta-analyses showing conver-
sion rates of 29–32% at 36 months follow-up (4, 6), our study had 
a low conversion rate of 14.6%. A study of 82 UHR individuals 
showed that 100% of the DAOA rs1341402 CC genotype carriers 
(n = 4) compared to 50% of the DAOA rs778294 AA genotype 
carriers (n = 10; A-allele protective against schizophrenia) pro-
gressed to psychosis within 24 months (13). However, a recent 
study with 225 UHR individuals did not replicate these findings 
(14). Furthermore, another study of 67 UHR individuals showed 
that 100% of TT genotype carriers (n = 25) of NRG1 rs62510682 
developed psychosis within 12-months (12), but this finding 
was not replicated in the aforementioned study with 225 UHR 
individuals (14). About 46% of the NRG1 rs4281084 AA genotype 
UHR carriers (n =  13) and 44% of the T-allele UHR carriers 
(n =  45) transitioned to psychosis within a 15-year follow-up 
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period (14). Thus, there is ambiguity regarding the association 
of DAOA and NRG1 polymorphisms with the transition to psy-
chosis. We did not assess the aforementioned DAOA and NRG1 
SNPs in this study as we only focused on the SNPs associated with 
schizophrenia (10, 43).
Our finding that NRG1 rs10503929 TT genotype carriers 
had significantly less disorganized symptoms than the dominant 
(CC + CT) genotype carriers at baseline (RDoC cognitive control) 
is consistent with previous finding of a significant association of 
NRG1 rs10503929 with cognitive domains (abstraction and men-
tal flexibility, attention, and verbal memory) in schizophrenia 
patients, in which the C-allele (protective against schizophrenia) 
was associated with decreased cognitive performance (55). We 
found that NRG1 rs10503929 (CT +  TT) versus CC genotype 
carriers had nominally more auditory perception disturbances. 
To our knowledge, there are no previous studies on associations 
between the NRG1 rs10503929 (exon 8/9/10) and perceptual 
disturbances. However, a study in adolescents demonstrated 
that NRG1 rs3924999 (exon 2) was associated with perceptual 
disturbances (56).
The nominal associations between DAOA rs746187 and the 
RDoC-negative valence system: loss, and that between DAOA 
rs3916971 and the RDoC cognitive system: visual perception, 
points to the possible role of DAOA variations in modulating 
endophenotypes underlying psychosis risk. A recent study found 
a nominal association of DAOA rs3916971 with a psychotic disor-
der (57). Another study conducted in healthy male controls found 
that DAOA rs3916971 schizophrenia risk C-allele carriers had 
worse visual-spatial skills (58, 59). In our study, DAO rs3918347 
GA + AA genotype carriers experienced nominally more audi-
tory perception disturbances than GG genotype carriers at base-
line (RDoC cognitive system). Another study found a negative 
association of DAO rs3918346 with neurocognitive functioning 
in schizophrenia patients (60). Therefore, the association of DAO 
and DAOA SNPs with hopelessness and perception disturbances 
of our study needs further confirmation.
We further found that NRG1 mRNA levels increased with 
higher CDSS hopelessness scores. Previous postmortem studies 
have shown increased NRG1 mRNA levels in the hippocampus 
(61) and prefrontal cortex (62, 63) of schizophrenia patients com-
pared to that of healthy controls. Moreover, studies have shown 
dysfunctions in these regions might lead to hopelessness (64–66).
We examined associations of DAO, DAOA, and NRG1 SNPs 
with risk profiles in individuals at risk for psychosis. For the sake 
of higher homogeneity, we also focused on the APSS subsample, 
a classification that the DSM-5 working group included under 
“conditions for further study” (67). We found that the schizo-
phrenia risk G-allele of DAO rs3918347 had a tendency to be 
a risk allele for APSS compared to the remaining help-seeking 
group. This result has to be interpreted cautiously because the 
help-seeking group is not a healthy control group, but a mixed 
group of BLIPS, state-trait risk criterion, and HR.
We did not find any significant differences in NRG1 mRNA 
levels between converters to schizophrenia spectrum disorders 
versus non-converters, and APSS versus all other help-seeking 
non-converters, which might be due to small subsample size 
leading to modest power (Tables S3 and S4 in Supplementary 
Material) and heterogeneous subgroups. Our results are in con-
trast to a study, which showed that NRG1 (type I and II isoforms) 
mRNA expression was significantly lower in blood of UHR indi-
viduals who transitioned to psychosis (n = 31) compared to non-
converters (n = 66) and controls (n = 50) (68). The discrepancy in 
the results of our study and the aforementioned study might also 
be due to the differences in isolation method, number of reference 
genes, stability of the reference genes, and normalization method 
used to normalize NRG1 mRNA levels to reference genes. A study 
conducted on immortalized lymphocytes showed that there was 
no difference in NRG1 mRNA levels between schizophrenia 
patients and healthy controls (69).
We were unable to detect DAO and DAOA mRNA using 
qRT-PCR in the whole blood of individuals at-risk for psychosis, 
which is in line with a study that used RNA sequencing to detect 
DAO and DAOA mRNA in healthy participants (70). As qRT-
PCR can detect low copy number genes (71), undetectable DAO 
and DAOA mRNA levels might suggest either very low expression 
below the detection limit of qRT-PCR or extremely localized 
expression (44). The reasons for very low or no expression of 
DAO and DAOA mRNA in blood might be highly methylated 
(75–90%) Illumina CpG sites of DAO and DAOA genes in healthy 
individuals (72). Another reason for this low or no expression 
might be the expression of these genes specifically in the brain 
(47, 73) because of their role in glutamatergic neurotransmission 
via NMDA receptors (25).
In our study, DAO rs4623951 genotype data showed that the 
study population deviated from the HWE. Since we controlled 
for genotyping errors, this deviation from HWE might be due to 
the observed excess of CT heterozygotes (54%). This excess het-
erozygosity might be caused by “selection favoring heterozygotes, 
outbreeding, and negative assortative mating” (74). As deviation 
from the HWE creates bias in the associations reported (75), the 
association results of DAO rs4623951 SNP should be interpreted 
with caution. As this study did not have all the instruments sug-
gested by RDoC for negative valence and cognitive systems, we 
used an exploratory approach, using the instruments available in 
this study to create the respective constructs. Thus, future studies 
are needed to confirm our RDoC findings.
Our study has several limitations, which must be acknowl-
edged. Although a total of 185 individuals at risk for psychosis 
were recruited, sample sizes within genotypes across clinical 
and RDoC domains were small and the power of the study was 
modest. In this study, only a small percentage (14.6%) of at-risk 
individuals converted to schizophrenia at 36 months follow-up, 
50% of individuals dropped out of the study before 36 months, 
and there was no healthy control group. The conversion status of 
the dropouts is unknown, and thus, it is not possible to reliably 
determine the conversion rate. The group of all other help seeking 
individuals was at heterogeneous risk (BLIPS, state-trait criteria, 
COPER, COGDIS). The sample size at 36-month follow-up for 
different psychopathology scales was small because of the high 
dropout rate. To circumvent this problem, we used the last 
psychopathology assessment available from each individual. 
Therefore, the results of LA until 36  months should be inter-
preted with caution, as they are not based on a homogeneous 
36-month follow-up score. We studied only few genes (three 
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genes) and a relatively small number of their polymorphisms 
(six SNPs), which might be the reason for not finding markers 
for predicting conversion to schizophrenia spectrum disorders. 
However, these genes and their polymorphisms are still of inter-
est due to their importance in glutamatergic neurotransmission. 
This study also has strengths, which needs to be highlighted. 
We recruited individuals from a broad age range (13–35 years) 
and used age-specific scales (e.g., SPI-A/SPI-CY). Most of the 
published literature in at-risk population has focused on clinical 
phenotypes. This study used both clinical phenotypes and RDoC 
domains, especially negative valence and cognitive systems, due 
to the role of the studied genes in the glutamate hypothesis of 
schizophrenia.
In summary, although DAO, DAOA, and NRG1 SNPs did not 
emerge as predictive markers for conversion to schizophrenia 
spectrum disorders, future association studies with larger cohorts, 
and longer follow-ups are needed to confirm the role of these 
genes in transition to schizophrenia spectrum disorders in the 
at-risk population. We also identified an association between the 
studied glutamatergic variants and RDoC-negative valence and 
cognitive systems, which indirectly implicates the role of these 
genetic variants in the glutamate hypothesis of schizophrenia. 
Future studies using RDoC domains might help to determine 
specific endophenotypes within at-risk populations. This might 
provide clinically useful, genetically informed risk prediction for 
dimensional and categorical outcomes among populations who 
maybe at-risk for developing psychosis.
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